The management of type 2 diabetes increasingly requires treatment decisions that go beyond achieving glycemic targets. While metformin remains an important therapy for many individuals, the choice of a second glucose-lowering agent should be individualized based on comorbidities, treatment goals, hypoglycemia risk, weight considerations, affordability, and patient preferences. Current ADA 2026 recommendations emphasize selecting therapies according to cardiovascular, kidney, weight, safety, cost, and other patient-specific factors. Join our expert webinar “Beyond Metformin: How I Choose the Right Second Drug” with Dr. P.

R. Vishanth on 10 th August 2026 at 3:00 PM IST to explore a practical, patient-centered approach to selecting the right second-line therapy. Stay Tuned! ##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to…